Aortic Valve Market Opportunities by Types, Demand, Top Manufacturers and Applications in Grooming Regions

11/giu/2019 06:34:48 Pramod Kumar Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The global aortic valve market is forecast to $ 13.6 billion by 2025, according to P&S Market Research.

The market is mainly driven by increasing prevalence of valvular diseases, increasing demand for minimally invasive surgeries (MISs), and increasing numbers of clinical trials and heart valves.

The various types of valves available in the aortic valve market are transcatheter valves, sutureless valves and others. Among these, transcatheter valves attained the largest share of 58.8% in the market, in 2017. This is the largest share in the market. For instance, In December 2017, Edwards Lifesciences Corporation announced new data demonstrating the economic advantages of the company's SAPIEN 3 transcatheter aortic valve.

Request to Get the Sample Pages at:    https://www.psmarketresearch.com/market-analysis/aortic-valve-market/report-sample

During the forecast period, the aortic valve is expected to witness the fastest growth in demand in Asia Pacific (APAC), at a CAGR of 13.0%, rising to the number of patient population with cardiovascular diseases, rising number of aortic valve replacement surgeries, growing medical tourism, and continuously improving healthcare infrastructure.

Make Inquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=aortic-valve-market

Moreover, economic development and rising healthcare are some of the factors that are expected to boost the APAC aortic valve market over the forecast period. Growing number of approvals for transcatheter valves by companies such as Edwards Lifesciences Corporation, Medtronic plc, and others is also expected to contribute to the growth of the market. For instance, in March 2018, LivaNova plc announced the first patient enrolment in the Perceval Valve clinical study for Chinese Registration ("PERFECT") TRIAL. This pre-market, prospective, single-arm trial study is being conducted to demonstrate the safety and effectiveness of Perceval Valve.

Globally, key players in the aortic valve industry are seeking for the approval of new products in the market. For instance, in February 2018, Edwards Lifesciences Corporation received CE Mark for its self-expanding CENTERA valve for severe, symptomatic aortic stenosis patients at high risk of open surgery. In March 2018, LivaNova Plc received CE Approval for its Bicarbon aortic valves for use with low-dose anticoagulant therapy. This document is based on evidence from the LOWERING-IT trial.

Some of the other key players operating in the aortic valve market are Medtronic plc and Boston Scientific Corporation.

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl